Using the immune system to fight cancer: an interview with Dr Charles Akle

Why does cancer occur?We all produce as many as 100,000 different types of cancer cells every day, which are recognized and eliminated by our extraordinarily efficient immune system.However, if someth

Updated on: October 27,2023

Using the immune system to fight cancer: an interview with Dr Charles Akle

Why does cancer occur?We all produce as many as 100,000 different types of cancer cells every day, which are recognized and eliminated by our extraordinarily efficient immune system.However, if someth

Updated on:October 27,2023

Multimodal sequencing achieves high-quality results from small volumes of frozen tumor specimens

byColumbia University School of Engineering and Applied ScienceA Circos plot representing the results of matched T-cell receptor sequencing collected on a patient undergoing anti-PD1 therapy. Co

Updated on: December 21,2023

Multimodal sequencing achieves high-quality results from small volumes of frozen tumor specimens

byColumbia University School of Engineering and Applied ScienceA Circos plot representing the results of matched T-cell receptor sequencing collected on a patient undergoing anti-PD1 therapy. Co

Updated on:December 21,2023

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK

Updated on: October 11,2023

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK

Updated on:October 11,2023

Colorectal cancer risk remains despite modern treatment for ulcerative colitis

byKarolinska InstitutetJonas Ludvigsson, professor in the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet in Sweden. Credit: Gustav MårtenssonPatients with the infl

Updated on: December 20,2023

Colorectal cancer risk remains despite modern treatment for ulcerative colitis

byKarolinska InstitutetJonas Ludvigsson, professor in the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet in Sweden. Credit: Gustav MårtenssonPatients with the infl

Updated on:December 20,2023

Exploring key regulators of programmed cell death in melanoma and the immune system's response

byBrigham and Women’s HospitalExpression of type I interferon receptors by melanoma cells. Credit:Nature Communications(2024). DOI: 10.1038/s41467-024-51496-2A new paperpublish

Updated on: September 10,2024

Exploring key regulators of programmed cell death in melanoma and the immune system's response

byBrigham and Women’s HospitalExpression of type I interferon receptors by melanoma cells. Credit:Nature Communications(2024). DOI: 10.1038/s41467-024-51496-2A new paperpublish

Updated on:September 10,2024

Targeted lung cancer drug shows promise in phase I/II clinical trial

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainEarly trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain t

Updated on: December 19,2023

Targeted lung cancer drug shows promise in phase I/II clinical trial

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainEarly trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain t

Updated on:December 19,2023

Cell therapy could improve bone marrow transplant safety

by Tiare Dunlap,University of California, Los AngelesGraphical abstract. Credit:iScience(2022). DOI: 10.1016/j.isci.2022.104859UCLA researchers report a step forward in the developme

Updated on: January 10,2024

Cell therapy could improve bone marrow transplant safety

by Tiare Dunlap,University of California, Los AngelesGraphical abstract. Credit:iScience(2022). DOI: 10.1016/j.isci.2022.104859UCLA researchers report a step forward in the developme

Updated on:January 10,2024

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Updated on: October 15,2023

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Updated on:October 15,2023

Review of American newspapers reveals positive coverage of lung cancer screening

byAmerican Roentgen Ray SocietyKey developments in lung cancer screening are annotated by year. Study period included only first 3 months of 2022, resulting in lower number of articles for that

Updated on: December 20,2023

Review of American newspapers reveals positive coverage of lung cancer screening

byAmerican Roentgen Ray SocietyKey developments in lung cancer screening are annotated by year. Study period included only first 3 months of 2022, resulting in lower number of articles for that

Updated on:December 20,2023

Potential new treatment for angioimmunoblastic T-cell lymphoma

byUniversity of TsukubaCredit: AI-generated imageA type of blood cell cancer called angioimmunoblastic T-cell lymphoma (AITL) can develop as mutations accumulate with age in the stem cells from

Updated on: December 18,2023

Potential new treatment for angioimmunoblastic T-cell lymphoma

byUniversity of TsukubaCredit: AI-generated imageA type of blood cell cancer called angioimmunoblastic T-cell lymphoma (AITL) can develop as mutations accumulate with age in the stem cells from

Updated on:December 18,2023

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe

Updated on: December 19,2023

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe

Updated on:December 19,2023

B cells linked to effective cancer immunotherapy

by Göran B Jönsson,Lund UniversityImmunofluorescence analysis of a melanoma tumor showing that B cells in B cell clusters express CXCR5, a marker for tertiary lymphoid structures. Credit: Göran

Updated on: December 20,2023

B cells linked to effective cancer immunotherapy

by Göran B Jönsson,Lund UniversityImmunofluorescence analysis of a melanoma tumor showing that B cells in B cell clusters express CXCR5, a marker for tertiary lymphoid structures. Credit: Göran

Updated on:December 20,2023